%PDF-1.4
%
301 0 obj
<>
endobj
291 0 obj
<>
endobj
290 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows)
Arbortext Advanced Print Publisher 10.0.1465/W Unicode
2017-01-07T06:34:03-08:00
2016-04-28T22:02:38+05:30
2017-01-07T06:34:03-08:00
application/pdf
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
uuid:f950a0ec-900c-4a0d-b597-7e3d38831995
uuid:7a92f601-1dd2-11b2-0a00-1e002868f9ff
endstream
endobj
302 0 obj
<>
endobj
189 0 obj
<>
endobj
288 0 obj
<>
endobj
5 0 obj
<>
endobj
385 0 obj
<>
endobj
386 0 obj
<>
endobj
64 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 65 0 R/Type/Page>>
endobj
75 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 76 0 R/Type/Page>>
endobj
94 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 95 0 R/Type/Page>>
endobj
137 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 138 0 R/Type/Page>>
endobj
387 0 obj
<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Type/Page>>
endobj
388 0 obj
<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
411 0 obj
[413 0 R 414 0 R 415 0 R 416 0 R 417 0 R]
endobj
412 0 obj
<>stream
BT
/T1_0 1 Tf
12 0 0 12 84 741 Tm
(Notes)Tj
ET
84 182 m
511 182 l
0 0 m
S
BT
ET
BT
0 0 1 rg
/T1_0 1 Tf
10 0 0 10 84 143.99997 Tm
(http://group.bmj.com/group/rights-licensing/permissions)Tj
0 g
/T1_1 1 Tf
0 1 TD
(To request permissions go to:)Tj
ET
BT
0 0 1 rg
/T1_0 1 Tf
10 0 0 10 84 109.99997 Tm
(http://journals.bmj.com/cgi/reprintform)Tj
0 g
/T1_1 1 Tf
T*
(To order reprints go to:)Tj
ET
BT
0 0 1 rg
/T1_0 1 Tf
10 0 0 10 84 75.99997 Tm
(http://group.bmj.com/subscribe/)Tj
0 g
/T1_1 1 Tf
T*
(To subscribe to BMJ go to:)Tj
ET
BT
0 0 1 rg
/T1_1 1 Tf
8 0 0 8 399.55188 780 Tm
(group.bmj.com)Tj
0 g
-15.73099 0 Td
( on January 7, 2017 - Published by )Tj
0 0 1 rg
-8.28097 0 Td
(http://ard.bmj.com/)Tj
0 g
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
408 0 obj
<>
endobj
393 0 obj
<>
endobj
413 0 obj
<>
endobj
414 0 obj
<>
endobj
415 0 obj
<>
endobj
416 0 obj
<>
endobj
417 0 obj
<>
endobj
422 0 obj
<>
endobj
421 0 obj
<>
endobj
420 0 obj
<>
endobj
419 0 obj
<>
endobj
418 0 obj
<>
endobj
406 0 obj
[423 0 R 424 0 R 425 0 R 426 0 R 427 0 R 428 0 R 429 0 R 430 0 R 431 0 R 432 0 R 433 0 R 434 0 R 435 0 R 436 0 R 437 0 R 438 0 R]
endobj
407 0 obj
<>stream
q
61.5 0 0 38.75 103.25 714.25 cm
/Im0 Do
Q
BT
/T1_0 1 Tf
15 0 0 15 184 662.99985 Tm
(extension study)Tj
0 1 TD
(continuing CT-P13 in the PLANETRA)Tj
T*
(reference infliximab to CT-P13 and )Tj
0 1.00001 TD
(arthritis: comparison between switching from)Tj
0 1 TD
(infliximab\) in patients with rheumatoid )Tj
T*
(Efficacy and safety of CT-P13 \(biosimilar)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 184 618.99991 Tm
(Joon Lee, SuYeon Kim and Won Park)Tj
T*
(Abud-Mendoza, Boycho Oparanov, Svitlana Smiyan, HoUng Kim, Sang)Tj
0 1.00001 TD
(Edgar Ramiterre, Allan Lanzon, Asta Baranauskaite, Piotr Wiland, Carlos \
)Tj
0 1 TD
(Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, Pedro Miranda,)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 256.80002 595 Tm
( published online April 29, 2016)Tj
/T1_2 1 Tf
-7.28 0 Td
(Ann Rheum Dis\240)Tj
ET
84 581 m
511 581 l
0 0 m
S
BT
ET
BT
/T1_1 1 Tf
10 0 0 10 195.12003 536.99994 Tm
( )Tj
0 0 1 rg
/T1_0 1 Tf
-1.112 0 Td
(86)Tj
T*
(http://ard.bmj.com/content/early/2016/04/29/annrheumdis-2015-2087)Tj
0 g
/T1_1 1 Tf
0 1.00001 TD
(Updated information and services can be found at: )Tj
ET
84 523 m
511 523 l
0 0 m
S
BT
ET
BT
/T1_2 1 Tf
10 0 0 10 184 495 Tm
(These include:)Tj
ET
BT
/T1_0 1 Tf
12 0 0 12 99.30817 475 Tm
(References)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 222.36017 456.99994 Tm
( )Tj
0 0 1 rg
-2.72401 0 Td
(#BIBL)Tj
/T1_0 1 Tf
-1.11201 0 Td
(86)Tj
0 1 TD
(http://ard.bmj.com/content/early/2016/04/29/annrheumdis-2015-2087)Tj
0 g
/T1_1 1 Tf
0 1.00001 TD
(This article cites 39 articles, 9 of which you can access for free at: )Tj
ET
BT
/T1_0 1 Tf
12 0 0 12 87.96826 437 Tm
(Open Access)Tj
ET
BT
0 0 1 rg
/T1_1 1 Tf
10 0 0 10 286.80978 388.99985 Tm
(http://creativecommons.org/licenses/by-nc/4.0/)Tj
0 g
-10.28098 0 Td
(non-commercial. See: )Tj
0 1 TD
(provided the original work is properly cited and the use is)Tj
0 1.00001 TD
(non-commercially, and license their derivative works on different terms,\
)Tj
0 1 TD
(permits others to distribute, remix, adapt, build upon this work)Tj
T*
(Commons Attribution Non Commercial \(CC BY-NC 4.0\) license, which )Tj
0 1.00001 TD
(This is an Open Access article distributed in accordance with the Creati\
ve)Tj
ET
BT
/T1_0 1 Tf
12 0 0 12 119.29999 356.99997 Tm
(service)Tj
-2.83299 1 Td
(Email alerting)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 184 360.99997 Tm
(box at the top right corner of the online article. )Tj
0 1 TD
(Receive free email alerts when new articles cite this article. Sign up i\
n the)Tj
ET
84 334 m
511 334 l
0 0 m
S
BT
ET
BT
/T1_0 1 Tf
12 0 0 12 95.98444 295.99997 Tm
(Collections)Tj
3.00099 1 Td
(Topic)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 184 310 Tm
(Articles on similar topics can be found in the following collections )Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 283.46979 240.99985 Tm
( \(3258\))Tj
0 0 1 rg
-8.94698 0 Td
(Rheumatoid arthritis)Tj
0 g
12.28098 1 Td
( \(4951\))Tj
0 0 1 rg
-12.28098 0 Td
(Musculoskeletal syndromes)Tj
0 g
13.55896 1.00001 Td
( \(5144\))Tj
0 0 1 rg
-13.55896 0 Td
(Immunology \(including allergy\))Tj
0 g
11.78299 1 Td
( \(4641\))Tj
0 0 1 rg
-11.78299 0 Td
(Degenerative joint disease)Tj
0 g
11.616 1 Td
( \(4253\))Tj
0 0 1 rg
-11.616 0 Td
(Connective tissue disease)Tj
0 g
5.836 1.00001 Td
( \(579\))Tj
0 0 1 rg
-5.836 0 Td
(Open access)Tj
ET
84 227 m
511 227 l
0 0 m
S
BT
ET
84 182 m
511 182 l
0 0 m
S
BT
ET
BT
/T1_0 1 Tf
10 0 0 10 84 143.99997 Tm
(http://group.bmj.com/group/rights-licensing/permissions)Tj
0 g
/T1_1 1 Tf
T*
(To request permissions go to:)Tj
ET
BT
0 0 1 rg
/T1_0 1 Tf
10 0 0 10 84 109.99997 Tm
(http://journals.bmj.com/cgi/reprintform)Tj
0 g
/T1_1 1 Tf
T*
(To order reprints go to:)Tj
ET
BT
0 0 1 rg
/T1_0 1 Tf
10 0 0 10 84 75.99997 Tm
(http://group.bmj.com/subscribe/)Tj
0 g
/T1_1 1 Tf
T*
(To subscribe to BMJ go to:)Tj
ET
BT
0 0 1 rg
/T1_1 1 Tf
8 0 0 8 399.55188 780 Tm
(group.bmj.com)Tj
0 g
-15.73099 0 Td
( on January 7, 2017 - Published by )Tj
0 0 1 rg
-8.28097 0 Td
(http://ard.bmj.com/)Tj
0 g
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
410 0 obj
<>/Filter/FlateDecode/Height 155/Length 8612/Name/X/Subtype/Image/Type/XObject/Width 246>>stream
H pƿk$!@` ghôUZ툢APutZ:mv@P
6ElBHH ٜ{dw~IQBog&;v>G)""Nk-B8E'ҷD!H"[p"}No-B8E'ҷD!H"[p"}No-B8E'ҷD!H"[p"}No-B8E'ҷD!H"[p"}No%ᒌN)5\-ya|i;Y(+]|JAnjİ(&O&˼$&2j'3QX(A3K㕎e*I槬l"/o,FkwmEӲf>QmyIxǂ =b[;vwK>G/q,md(2//3~W=>)×ţAq`Pr=N?:~Kkۺ+G_?oz;|^|Tl`4[z\k7} L[eO{O[7{]ȟ_W;x,=p
aS8Nk:;ܭAe4qZw}<1T]^w(8wLfkۗŎaT`ݞC{>ss|o|厘a5tZ[o@^>#j`N8d/8az7*VF"V9fogm^KkoX-Bϱ˽_d| $ի->!H,L1olzhD |HHV#㑶Cn\X6=C(&|?nV/M1%Lx;(RԷ˶ 6a.1ᅵzPH9RqR+C3/^^X\08]eab/imxN)NbNss/TL)ehbS&*&|Ƒp=uBҶp;"L(5w5Z$%Xt??^lV41oUvw[5* N8@m[>jF
ZS Qxѿ|| ;*jڸS!-ZwˬpUZM\ h
xټ`<ԷïsXxN)W]6ASqpJqOnth
q!KMNRVȋ*G/Qls6Kc+Ũ|l_?* J"|xbUJ8y들MI08R-S/{]JoB8Ɇ 5mgl_RH#>]{+^GG>wX?
Eg$q٩)9,3!z_?!w;-/*?TC=F`S*Aw2ײ s=q]+JҬlإ@>9tŽW,gx
p5ׂMx^dQq,IPnTԶz
.Gyi_fIXN23p]Ӝ4c^`eڤ1~rxN]e'̌
ax@(B[xkV`]~յtM_*/x~W(9GW=t6 U;P0UT^qZǦKrsvaa`]|\8jLxZVxO^2x$+*nԌ!
VщߛT
9p|T\jQ$|X %?$[rjuMgR#DTuynbOv7hތ#2yQM#/pGQc)/ٍ~t_#o<5psGp㸖cw f[mwG҂;)}wJzvK+:P#w pzVH7^=Z3% -eYFgZ rjbfw߮DpI%WޤLsbT\y_xR5;.(>qw&kF8wz|VW9g_s8K82kṙf>'P
?n:r71 @SSR*J{x@fNٹ.Im֭;LWjhˮ&3&:kyJf#sɱbg=
ǟpVLCDyTW]^b
XƁ;X6jC8@} e%uq+M7)/l2+>itP"ɸv,a
P /pG1S
gUc_D{]Z;(re5 <Щ%2LċR-[70sLŢ)3*_} 7q^q\J_l'e2C9@I[@(`&ܴ0IaJq !3O r!daL4G
Em_uKk0N
oed{>VDTPE$7s56p+z8#я`z%RL! `/(gaL|]}Ska;Ě,Y@MXR}?)|K8ҵ;~k @ѯr{ΙBr5-?rVkG*<&=:Z)2-boi?S?!x 2-Fjpqqpݾy{qM__T!8RLVǤhExlO{ƍ*?/kєY/Gd&luy)R5|H8ic0HB"}~ sspP*(Fƣ[lL.ls;έfu1zL'@.- KQRBVQMKj'̄=+=l'5_iaDN3?-~r?f ?Nm3XA%{6@JU6JKv_Ik!v!5~XM}NǛ*U!&duͨ9mE"\ƕZOsp=6͋L5dAhz|5J8ٰ-b@
uڟO!Cv.#)8C뚘GIΟrZv1
~)_\Te ^B2{3A}su$#a]M(űO՞g
|b4qR>S]V63D!:$H*ZּlW&[oVk4'<>|%ŃԨ` ؞3 grGL!G1f?LQ T
xE/H&Fك6Ӳ-O%(RjT@g>qǁqVh'UBן$/lp>Α!5*NpTWM)1H%rΤ.ЕťM;>yȥ&E;}C?)ΖT.izzr1Fe$(nl;]#۫_fZR<{,0@jH,u5
URHL+(e&8,~F; 00bE.rx~B(xF$.Z
M?[7P2pFcۚnV@x*4PLH8wf8LUG).c:;G}F_xG`{lPp%W͟P&!rp`9J9UpbuM{i0.kR`>LW|Mo\l`@&
H{̷m22#0qDӄY+}˂zpȒ0)N5xrj{WO7M1%k5%k1n{MppL%T廝`ÃqppsK Tvw焃_L}~$FV~ng|3^!<+ǾT>v8B꘦MUZm$;٥f}R0fbpp